Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 262.22 | — | — | — | 53.44 | 835.23 | 448.84 | — | 313.50 | 88.24 | 59.54 | — | 34.68 | 16.45 | 10.27 | — | — | 88.18 | 30.90 | — | — |
| — | — | — | — | -83.0% | +846.5% | +653.9% | — | +803.9% | +436.5% | +479.9% | — | — | -81.3% | -66.8% | — | — | — | — | — | — | |
| P/S Ratio | 4.62 | 5.70 | 7.07 | 4.88 | 6.27 | 7.05 | 8.92 | 11.10 | 12.62 | 12.34 | 16.50 | 18.12 | 4.30 | 3.14 | 2.21 | 4.44 | 3.92 | — | 196.10 | 43.94 | 210.37 |
| — | -19.2% | -20.8% | -56.0% | -50.4% | -42.9% | -45.9% | -38.7% | +193.4% | +293.3% | +645.3% | +308.3% | +9.6% | — | -98.9% | -89.9% | -98.1% | — | -46.4% | -82.9% | -47.2% | |
| P/B Ratio | 4.28 | 4.02 | 4.65 | 5.11 | 5.58 | 5.83 | 7.55 | 12.58 | 13.07 | 13.33 | 20.20 | 141.07 | 156.81 | 3.77 | 2.29 | 7.00 | 15.59 | 21.26 | 23.00 | 10.44 | 31.85 |
| — | -31.0% | -38.4% | -59.4% | -57.3% | -56.3% | -62.6% | -91.1% | -91.7% | +253.6% | +781.0% | +1915.2% | +906.0% | -82.3% | -90.0% | -32.9% | -51.1% | -11.1% | +11.5% | -62.1% | +110.4% | |
| P/FCF | — | — | 53.02 | — | 47.97 | 104.32 | — | — | 327.34 | — | 168.99 | 475.30 | 24.59 | 44.77 | 6.36 | 114.79 | — | — | — | — | — |
| — | — | — | — | -85.3% | — | — | — | +1231.0% | — | +2555.9% | +314.1% | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 35.91 | — | — | 211.85 | 23.99 | 63.99 | 68.89 | 287.34 | 67.61 | 87.89 | 51.96 | — | 10.59 | 16.37 | 7.01 | 24.88 | 22.46 | — | — | — | — |
| — | — | — | -26.3% | -64.5% | -27.2% | +32.6% | — | +538.4% | +436.9% | +640.8% | — | -52.9% | — | — | — | — | — | — | — | — | |
| EV / EBIT | 43.78 | — | — | — | 23.82 | 82.85 | 41.73 | 462.87 | 80.98 | 50.97 | 35.33 | — | 10.76 | 17.42 | 7.32 | — | — | 7.78 | 18.56 | — | — |
| — | — | — | — | -70.6% | +62.5% | +18.1% | — | +652.8% | +192.6% | +383.0% | — | — | +123.9% | -60.6% | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.4% | 92.4% | 94.6% | 95.3% | 94.7% | 95.7% | 95.9% | 95.8% | 96.2% | 96.9% | 96.4% | 95.4% | 96.3% | 96.3% | 95.5% | 95.2% | 95.2% | — | -0.5% | -0.6% | -4.0% |
| — | -3.4% | -1.5% | -0.5% | -1.6% | -1.3% | -0.5% | +0.4% | -0.1% | +0.6% | +1.0% | +0.2% | +1.1% | — | +19053.5% | +16694.9% | +2454.1% | — | +43.2% | +74.1% | -100.7% | |
| Operating Margin | 9.9% | -49.3% | -41.5% | 0.3% | 22.7% | 8.1% | 10.3% | 2.1% | 16.6% | 12.9% | 29.7% | -337.5% | 39.8% | 17.0% | 26.7% | 16.2% | 15.8% | — | -1851.5% | -832.5% | -1097.4% |
| — | -708.5% | -503.1% | -84.9% | +36.4% | -37.3% | -65.3% | +100.6% | -58.3% | -23.7% | +11.1% | -2188.9% | +152.5% | — | +101.4% | +101.9% | +101.4% | — | -21.1% | +10.3% | +39.1% | |
| Net Margin | 4.3% | -36.4% | -38.3% | -4.6% | 11.8% | 1.7% | 12.2% | -0.4% | 4.4% | 14.0% | 27.7% | -372.1% | 12.4% | 6.3% | 9.0% | -12.2% | -11.4% | — | 634.4% | -833.2% | -1097.8% |
| — | -2307.0% | -412.8% | -1204.1% | +167.8% | -88.2% | -55.9% | +99.9% | -64.5% | +121.4% | +208.0% | -2945.1% | +208.4% | — | -98.6% | +98.5% | +99.0% | — | +141.5% | +10.5% | +38.9% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.2% | -7.0% | -6.2% | -1.2% | 2.7% | 0.4% | 2.7% | -0.1% | 1.2% | 3.9% | 14.7% | -1156.6% | 7.9% | 1.9% | 2.7% | -6.9% | -6.2% | 97.3% | 14.8% | -39.9% | -34.6% |
| — | -1957.6% | -331.8% | -1124.7% | +130.9% | -90.2% | -81.8% | +100.0% | -85.1% | +102.7% | +450.6% | -16784.4% | +227.7% | -98.0% | -82.0% | +82.8% | +82.2% | +562.0% | +159.3% | -79.6% | -119.0% | |
| ROA | 3.4% | -5.9% | -5.3% | -1.1% | 2.3% | 0.3% | 2.1% | -0.1% | 0.9% | 2.9% | 6.3% | -159.7% | 6.6% | 1.7% | 2.3% | -6.0% | -5.8% | 83.5% | 10.5% | -30.3% | -28.0% |
| — | -1975.7% | -348.3% | -1240.0% | +153.4% | -89.2% | -66.5% | +100.0% | -86.1% | +73.5% | +174.3% | -2556.6% | +212.4% | -98.0% | -78.1% | +80.2% | +79.1% | +562.8% | +150.1% | -65.6% | -105.6% | |
| ROIC | 8.9% | -9.6% | -6.8% | 0.1% | 5.4% | 1.8% | 1.9% | 0.5% | 3.9% | 3.5% | 30.2% | — | 24.7% | 5.1% | 8.5% | 12.7% | 58.7% | — | — | -982.9% | -205.9% |
| — | -643.7% | -456.9% | -83.0% | +39.0% | -50.2% | -93.7% | — | -84.3% | -30.5% | +256.8% | — | -57.9% | — | — | +101.3% | +128.5% | — | — | -4001.5% | -938.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.00 | 0.03 | — | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 | 0.07 | 0.06 | 0.04 |
| — | +92.6% | -60.5% | -59.4% | -53.5% | -48.6% | +390.5% | -44.6% | — | +331.2% | -52.6% | +245.4% | — | -72.8% | -90.7% | -85.4% | -67.1% | -46.9% | +394.4% | +168.6% | +156.7% | |
| Debt / EBITDA | 0.07 | — | — | 1.15 | 0.15 | 0.50 | 0.56 | 1.50 | 0.38 | 0.56 | 0.03 | — | — | 0.09 | 0.09 | 0.13 | 0.08 | — | — | — | — |
| — | — | — | -23.0% | -59.7% | -11.4% | +1641.8% | — | — | +523.5% | -64.2% | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.60 | 4.26 | 4.64 | 5.60 | 6.19 | 5.40 | 3.60 | 3.32 | 3.72 | 3.44 | 3.22 | 2.85 | 2.88 | 3.30 | 3.67 | 4.06 | 18.40 | 18.86 | 2.78 | 3.63 | 4.29 |
| — | -21.1% | +28.6% | +68.6% | +66.3% | +57.0% | +12.0% | +16.3% | +29.4% | +4.1% | -12.2% | -29.6% | -84.4% | -82.5% | +31.7% | +11.6% | +329.1% | +203.2% | -66.1% | -27.7% | -33.2% | |
| Quick Ratio | 5.04 | 3.86 | 4.06 | 5.04 | 5.64 | 4.87 | 3.19 | 2.99 | 3.29 | 3.07 | 2.97 | 2.64 | 2.88 | 2.89 | 3.22 | 3.56 | 18.40 | 18.86 | 2.78 | 3.63 | 4.29 |
| — | -20.8% | +27.4% | +68.4% | +71.3% | +58.4% | +7.6% | +13.4% | +14.3% | +6.5% | -8.0% | -25.7% | -84.4% | -84.7% | +15.8% | -2.2% | +329.1% | +203.2% | -66.1% | -27.7% | -33.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -1.93 | -1200.83 | 506.20 | 580.62 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GYRE stock.
Gyre Therapeutics, Inc.'s current P/E is 262.2x. The average P/E over the last 1 quarters is 53.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Gyre Therapeutics, Inc.'s current operating margin is 9.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Gyre Therapeutics, Inc.'s business trajectory between earnings reports.